{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T21:53:01Z","timestamp":1774129981904,"version":"3.50.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T00:00:00Z","timestamp":1621036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T00:00:00Z","timestamp":1621036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Malignant melanoma is the third most common primary in the diagnosis of brain metastases. Stereotactic radiosurgery (SRS) is a well-established treatment option in limited brain disease. We analyzed outcomes of SRS with a particular focus on the graded prognostic assessment (GPA, melanoma molGPA), prognostic factors, and toxicity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We evaluated 173 brain metastases in 83 patients with malignant melanoma. All were treated with SRS median dose of 20\u00a0Gy prescribed to the 80 or 100% isodose line between 2002 and 2019. All patients were followed-up regularly, including contrast\u2010enhanced brain imaging as well as clinical examination, initially 6\u00a0weeks after treatment, then in quarterly follow-up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median age was 61\u00a0years (range 27\u201380); 36 female and 47 male patients were treated. After a median follow-up of 5.7\u00a0months, median OS (overall survival) was 9.7\u00a0months 95%-KI 4.7\u201314.7). LC (local control) at 6\u00a0months, 12, 24\u00a0months was 89%, 86%, and 72%, respectively (median was not reached). Median DBC (distant brain control) was 8.2\u00a0months (95%-KI 4.7\u201311.7). For OS, a KPS\u2009\u2265\u200980%, a positive BRAF mutation status, a small PTV (planning target volume), the absence of extracranial metastases, as well as a GPA and melanoma molGPA\u2009&gt;\u20092 were prognostic factors. In the MVA, a small PTV and a melanoma molGPA\u2009&gt;\u20092 remained significant.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The present survival outcomes support the use of the disease-specific melanoma molGPA as reliable prognostic score. Favorable outcomes for SRS compared to other studies were observed. In the treatment of brain metastases of malignant melanoma patients, a multidisciplinary approach consisting of surgery, SRS, chemotherapy, and immunotherapy should be considered.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12094-021-02607-8","type":"journal-article","created":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T17:02:36Z","timestamp":1621098156000},"page":"2020-2029","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Outcomes after stereotactic radiosurgery of brain metastases in patients with malignant melanoma and validation of the melanoma molGPA"],"prefix":"10.1007","volume":"23","author":[{"given":"K. A.","family":"Kessel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2016-0709","authenticated-orcid":false,"given":"A.","family":"Deichl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Gempt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Posch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Diehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. E.","family":"Combs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,15]]},"reference":[{"key":"2607_CR1","unstructured":"Hayat MA Brain Metastases from Primary Tumors Volume Three: Epidemiology, Biology, and Therapy of Melanoma and Other Cancers, ed. M.A. Hayat. 2016 Academic Press. 384."},{"issue":"1","key":"2607_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11060-009-0073-4","volume":"96","author":"ME Linskey","year":"2010","unstructured":"Linskey ME, et al. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96(1):45\u201368.","journal-title":"J Neurooncol"},{"issue":"5","key":"2607_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.7861\/clinmedicine.14-5-535","volume":"14","author":"K Spencer","year":"2014","unstructured":"Spencer K, Hall A, Jain P. Brain metastases. Clin Med (Lond). 2014;14(5):535\u20137.","journal-title":"Clin Med (Lond)"},{"issue":"Suppl","key":"2607_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3171\/JNS\/2008\/109\/12\/S14","volume":"109","author":"CM Sperduto","year":"2008","unstructured":"Sperduto CM, et al. A validation study of a new prognostic index for patients with brain metastases: the graded prognostic assessment. J Neurosurg. 2008;109(Suppl):87\u20139.","journal-title":"J Neurosurg"},{"issue":"6","key":"2607_CR5","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jamaoncol.2016.3834","volume":"3","author":"PW Sperduto","year":"2017","unstructured":"Sperduto PW, et al. Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA). JAMA Oncol. 2017;3(6):827\u201331.","journal-title":"JAMA Oncol"},{"issue":"3","key":"2607_CR6","doi-asserted-by":"publisher","first-page":"178","DOI":"10.14740\/jocmr3248w","volume":"10","author":"C Nieder","year":"2018","unstructured":"Nieder C, et al. Validation of the graded prognostic assessment for melanoma using molecular markers (Melanoma-molGPA). J Clin Med Res. 2018;10(3):178\u201381.","journal-title":"J Clin Med Res"},{"issue":"5","key":"2607_CR7","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1016\/j.ijrobp.2011.02.027","volume":"82","author":"PW Sperduto","year":"2012","unstructured":"Sperduto PW, et al. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys. 2012;82(5):2111\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2607_CR8","doi-asserted-by":"crossref","unstructured":"O'Beirn M et al. The expanding role of radiosurgery for brain metastases. Medicines (Basel), 2018.","DOI":"10.20944\/preprints201807.0455.v1"},{"issue":"1","key":"2607_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11060-009-0065-4","volume":"96","author":"SN Kalkanis","year":"2010","unstructured":"Kalkanis SN, Linskey ME. Evidence-based clinical practice parameter guidelines for the treatment of patients with metastatic brain tumors: introduction. J Neurooncol. 2010;96(1):7\u201310.","journal-title":"J Neurooncol"},{"issue":"8","key":"2607_CR10","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1200\/JOP.2016.012922","volume":"12","author":"SN Badiyan","year":"2016","unstructured":"Badiyan SN, Regine WF, Mehta M. Stereotactic radiosurgery for treatment of brain metastases. J Oncol Pract. 2016;12(8):703\u201312.","journal-title":"J Oncol Pract"},{"issue":"6","key":"2607_CR11","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00066-014-0648-7","volume":"190","author":"M Kocher","year":"2014","unstructured":"Kocher M, et al. Stereotactic radiosurgery for treatment of brain metastases. A report of the DEGRO working group on stereotactic radiotherapy. Strahlenther Onkol. 2014;190(6):521\u201332.","journal-title":"Strahlenther Onkol"},{"issue":"23","key":"2607_CR12","doi-asserted-by":"publisher","first-page":"4193","DOI":"10.1002\/cncr.32454","volume":"125","author":"G Schvartsman","year":"2019","unstructured":"Schvartsman G, et al. Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma. Cancer. 2019;125(23):4193\u2013202.","journal-title":"Cancer"},{"issue":"10","key":"2607_CR13","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1586\/ern.12.111","volume":"12","author":"E Fonkem","year":"2012","unstructured":"Fonkem E, et al. Melanoma brain metastasis: overview of current management and emerging targeted therapies. Expert Rev Neurother. 2012;12(10):1207\u201315.","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"2607_CR14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/bmb\/ldu019","volume":"111","author":"Corrie","year":"2014","unstructured":"Corrie, et al. Management of melanoma. Br Med Bull. 2014;111(1):149\u201362.","journal-title":"Br Med Bull"},{"issue":"11","key":"2607_CR15","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","volume":"13","author":"GV Long","year":"2012","unstructured":"Long GV, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(11):1087\u201395.","journal-title":"Lancet Oncol"},{"issue":"7","key":"2607_CR16","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","volume":"18","author":"MA Davies","year":"2017","unstructured":"Davies MA, et al. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017;18(7):863\u201373.","journal-title":"Lancet Oncol"},{"issue":"5","key":"2607_CR17","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","volume":"19","author":"GV Long","year":"2018","unstructured":"Long GV, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018;19(5):672\u201381.","journal-title":"Lancet Oncol"},{"issue":"8","key":"2607_CR18","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi HA, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379(8):722\u201330.","journal-title":"N Engl J Med"},{"issue":"6892","key":"2607_CR19","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949\u201354.","journal-title":"Nature"},{"issue":"6","key":"2607_CR20","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.molonc.2014.05.009","volume":"8","author":"J Seoane","year":"2014","unstructured":"Seoane J, De Mattos-Arruda L. Brain metastasis: new opportunities to tackle therapeutic resistance. Mol Oncol. 2014;8(6):1120\u201331.","journal-title":"Mol Oncol"},{"issue":"2","key":"2607_CR21","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3892\/or.2012.2139","volume":"29","author":"S Lwu","year":"2013","unstructured":"Lwu S, et al. Stereotactic radiosurgery for the treatment of melanoma and renal cell carcinoma brain metastases. Oncol Rep. 2013;29(2):407\u201312.","journal-title":"Oncol Rep"},{"issue":"13","key":"2607_CR22","doi-asserted-by":"publisher","first-page":"e486","DOI":"10.1016\/S1470-2045(15)00141-2","volume":"16","author":"T Ajithkumar","year":"2015","unstructured":"Ajithkumar T, et al. Evolving treatment options for melanoma brain metastases. Lancet Oncol. 2015;16(13):e486\u201397.","journal-title":"Lancet Oncol"},{"issue":"11","key":"2607_CR23","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1007\/s00106-005-1326-y","volume":"53","author":"ES Schultz","year":"2005","unstructured":"Schultz ES, Schuler G. Malignant melanoma. Diagnosis and therapy. HNO. 2005;53(11):928\u201339.","journal-title":"HNO"},{"issue":"5","key":"2607_CR24","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/j.prro.2018.02.006","volume":"8","author":"DJ Eaton","year":"2018","unstructured":"Eaton DJ, et al. Stereotactic radiosurgery for benign brain tumors: results of multicenter benchmark planning studies. Pract Radiat Oncol. 2018;8(5):e295\u2013304.","journal-title":"Pract Radiat Oncol."},{"key":"2607_CR25","doi-asserted-by":"crossref","unstructured":"Han EY et al. Dosimetric comparison of fractionated radiosurgery plans using frameless Gamma Knife ICON and CyberKnife systems with linear accelerator-based radiosurgery plans for multiple large brain metastases. J Neurosurg 2019: p. 1\u20137.","DOI":"10.3171\/2019.1.JNS182769"},{"key":"2607_CR26","doi-asserted-by":"crossref","unstructured":"Yomo S et al. The impact of EGFR-TKI use on clinical outcomes of lung adenocarcinoma patients with brain metastases after Gamma Knife radiosurgery: a propensity score-matched analysis based on extended JLGK0901 dataset (JLGK0901-EGFR-TKI). J Neurooncol, 2019.","DOI":"10.1007\/s11060-019-03282-0"},{"key":"2607_CR27","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.radonc.2018.08.025","volume":"130","author":"EJ Lehrer","year":"2019","unstructured":"Lehrer EJ, et al. Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international meta-analysis of individual patient data. Radiother Oncol. 2019;130:104\u201312.","journal-title":"Radiother Oncol"},{"issue":"4","key":"2607_CR28","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.ijrobp.2017.06.2454","volume":"99","author":"PW Sperduto","year":"2017","unstructured":"Sperduto PW, et al. Estimating survival in melanoma patients with brain metastases: an update of the graded prognostic assessment for melanoma using molecular markers (melanoma-molGPA). Int J Radiat Oncol Biol Phys. 2017;99(4):812\u20136.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"7","key":"2607_CR29","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1200\/JCO.2004.08.140","volume":"22","author":"KM Fife","year":"2004","unstructured":"Fife KM, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol. 2004;22(7):1293\u2013300.","journal-title":"J Clin Oncol."},{"issue":"8","key":"2607_CR30","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/cncr.25643","volume":"117","author":"J Zakrzewski","year":"2011","unstructured":"Zakrzewski J, et al. Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer. 2011;117(8):1711\u201320.","journal-title":"Cancer"},{"issue":"8","key":"2607_CR31","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1002\/cncr.25631","volume":"117","author":"TK Eigentler","year":"2011","unstructured":"Eigentler TK, et al. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer. 2011;117(8):1697\u2013703.","journal-title":"Cancer"},{"issue":"2","key":"2607_CR32","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1215\/15228517-2007-058","volume":"10","author":"JJ Raizer","year":"2008","unstructured":"Raizer JJ, et al. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol. 2008;10(2):199\u2013207.","journal-title":"Neuro Oncol."},{"issue":"8","key":"2607_CR33","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/sj.bjc.6605622","volume":"102","author":"M Staudt","year":"2010","unstructured":"Staudt M, et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer. 2010;102(8):1213\u20138.","journal-title":"Br J Cancer."},{"issue":"8","key":"2607_CR34","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/cncr.25634","volume":"117","author":"MA Davies","year":"2011","unstructured":"Davies MA, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer. 2011;117(8):1687\u201396.","journal-title":"Cancer"},{"issue":"5","key":"2607_CR35","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S0360-3016(01)02772-9","volume":"52","author":"C Yu","year":"2002","unstructured":"Yu C, et al. Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. Int J Radiat Oncol Biol Phys. 2002;52(5):1277\u201387.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"33","key":"2607_CR36","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1200\/JCO.19.01414","volume":"37","author":"AM Hong","year":"2019","unstructured":"Hong AM, et al. Adjuvant whole-brain radiation therapy compared with observation after local treatment of melanoma brain metastases: a multicenter, randomized phase III Trial. J Clin Oncol. 2019;37(33):3132\u201341.","journal-title":"J Clin Oncol."},{"issue":"3","key":"2607_CR37","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.ijrobp.2006.01.024","volume":"65","author":"C Gaudy-Marqueste","year":"2006","unstructured":"Gaudy-Marqueste C, et al. Gamma-Knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole-brain radiotherapy. Int J Radiat Oncol Biol Phys. 2006;65(3):809\u201316.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"3","key":"2607_CR38","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0360-3016(98)00272-7","volume":"42","author":"Y Mori","year":"1998","unstructured":"Mori Y, et al. Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys. 1998;42(3):581\u20139.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"Suppl","key":"2607_CR39","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3171\/JNS\/2008\/109\/12\/S19","volume":"109","author":"JW Powell","year":"2008","unstructured":"Powell JW, et al. Gamma Knife surgery in the management of radioresistant brain metastases in high-risk patients with melanoma, renal cell carcinoma, and sarcoma. J Neurosurg. 2008;109(Suppl):122\u20138.","journal-title":"J Neurosurg."},{"issue":"2","key":"2607_CR40","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S0360-3016(01)01622-4","volume":"51","author":"SN Sanghavi","year":"2001","unstructured":"Sanghavi SN, et al. Radiosurgery for patients with brain metastases: a multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. Int J Radiat Oncol Biol Phys. 2001;51(2):426\u201334.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2607_CR41","doi-asserted-by":"crossref","unstructured":"Sneed, P.K., et al., A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys, 2002. 53(3): p. 519\u201326.","DOI":"10.1016\/S0360-3016(02)02770-0"},{"issue":"9422","key":"2607_CR42","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(04)16250-8","volume":"363","author":"DW Andrews","year":"2004","unstructured":"Andrews DW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363(9422):1665\u201372.","journal-title":"Lancet"},{"issue":"34","key":"2607_CR43","doi-asserted-by":"publisher","first-page":"8870","DOI":"10.1200\/JCO.2005.01.8747","volume":"23","author":"R Manon","year":"2005","unstructured":"Manon R, et al. Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern cooperative oncology group study (E 6397). J Clin Oncol. 2005;23(34):8870\u20136.","journal-title":"J Clin Oncol."},{"issue":"2","key":"2607_CR44","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","volume":"29","author":"M Kocher","year":"2011","unstructured":"Kocher M, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952\u201326001 study. J Clin Oncol. 2011;29(2):134\u201341.","journal-title":"J Clin Oncol."},{"issue":"5","key":"2607_CR45","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1016\/j.ijrobp.2009.03.028","volume":"76","author":"JL Frazier","year":"2010","unstructured":"Frazier JL, et al. Stereotactic radiosurgery in the management of brain metastases: an institutional retrospective analysis of survival. Int J Radiat Oncol Biol Phys. 2010;76(5):1486\u201392.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"Suppl 1","key":"2607_CR46","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3171\/2016.8.GKS161359","volume":"125","author":"SX Bian","year":"2016","unstructured":"Bian SX, et al. Prognostic factors for melanoma brain metastases treated with stereotactic radiosurgery. J Neurosurg. 2016;125(Suppl 1):31\u20139.","journal-title":"J Neurosurg."},{"issue":"3","key":"2607_CR47","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ijrobp.2009.08.025","volume":"77","author":"PW Sperduto","year":"2010","unstructured":"Sperduto PW, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2010;77(3):655\u201361.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"3","key":"2607_CR48","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ejca.2013.11.002","volume":"50","author":"R Dummer","year":"2014","unstructured":"Dummer R, et al. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer. 2014;50(3):611\u201321.","journal-title":"Eur J Cancer."},{"issue":"16","key":"2607_CR49","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535\u201346.","journal-title":"N Engl J Med."},{"issue":"1","key":"2607_CR50","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23\u201334.","journal-title":"N Engl J Med."},{"issue":"9","key":"2607_CR51","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","volume":"17","author":"PA Ascierto","year":"2016","unstructured":"Ascierto PA, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248\u201360.","journal-title":"Lancet Oncol."},{"issue":"2","key":"2607_CR52","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3171\/2014.9.JNS141425","volume":"123","author":"D Ly","year":"2015","unstructured":"Ly D, et al. Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment. J Neurosurg. 2015;123(2):395\u2013401.","journal-title":"J Neurosurg."},{"key":"2607_CR53","unstructured":"Vogenberg FR, Isaacson Barash C, Pursel M Personalized medicine: part 1: evolution and development into theranostics. P T, 2010. 35(10): 560\u201376."},{"issue":"26","key":"2607_CR54","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1200\/JCO.2013.49.8691","volume":"31","author":"PA Ascierto","year":"2013","unstructured":"Ascierto PA, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol. 2013;31(26):3205\u201311.","journal-title":"J Clin Oncol."},{"issue":"3","key":"2607_CR55","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","volume":"15","author":"GA McArthur","year":"2014","unstructured":"McArthur GA, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323\u201332.","journal-title":"Lancet Oncol."},{"issue":"Suppl","key":"2607_CR56","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3171\/2014.8.GKS141421","volume":"121","author":"M Yamamoto","year":"2014","unstructured":"Yamamoto M, et al. Stereotactic radiosurgery for patients with multiple brain metastases: a case-matched study comparing treatment results for patients with 2\u20139 versus 10 or more tumors. J Neurosurg. 2014;121(Suppl):16\u201325.","journal-title":"J Neurosurg."},{"key":"2607_CR57","doi-asserted-by":"crossref","unstructured":"Serizawa T et al. Local tumor progression treated with Gamma Knife radiosurgery: differences between patients with 2\u20134 versus 5\u201310 brain metastases based on an update of a multi-institutional prospective observational study (JLGK0901). J Neurosurg, 2019: 1\u201310.","DOI":"10.3171\/2019.1.JNS183085"},{"key":"2607_CR58","doi-asserted-by":"crossref","unstructured":"Cao H et al. Dosimetric comparisons of different hypofractionated stereotactic radiotherapy techniques in treating intracranial tumors > 3 cm in longest diameter. J Neurosurg, 2019: 1\u20139.","DOI":"10.3171\/2018.12.JNS181578"},{"issue":"6","key":"2607_CR59","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.wneu.2013.02.025","volume":"82","author":"MT Neal","year":"2014","unstructured":"Neal MT, et al. Predictors of survival, neurologic death, local failure, and distant failure after gamma knife radiosurgery for melanoma brain metastases. World Neurosurg. 2014;82(6):1250\u20135.","journal-title":"World Neurosurg."},{"issue":"9","key":"2607_CR60","first-page":"5079","volume":"34","author":"D Rades","year":"2014","unstructured":"Rades D, et al. Radiosurgery alone for 1\u20133 newly-diagnosed brain metastases from melanoma: impact of dose on treatment outcomes. Anticancer Res. 2014;34(9):5079\u201382.","journal-title":"Anticancer Res."},{"issue":"2","key":"2607_CR61","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/(SICI)1520-6823(1997)5:2<72::AID-ROI5>3.0.CO;2-G","volume":"5","author":"M Gieger","year":"1997","unstructured":"Gieger M, et al. Response of intracranial melanoma metastases to stereotactic radiosurgery. Radiat Oncol Investig. 1997;5(2):72\u201380.","journal-title":"Radiat Oncol Investig."},{"issue":"Suppl 2","key":"2607_CR62","first-page":"790","volume":"62","author":"PD Brown","year":"2008","unstructured":"Brown PD, et al. Stereotactic radiosurgery for patients with \u201cradioresistant\u201d brain metastases. Neurosurgery. 2008;62(Suppl 2):790\u2013801.","journal-title":"Neurosurgery"},{"issue":"4","key":"2607_CR63","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/cncr.20447","volume":"101","author":"AE Radbill","year":"2004","unstructured":"Radbill AE, et al. Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity. Cancer. 2004;101(4):825\u201333.","journal-title":"Cancer"},{"key":"2607_CR64","doi-asserted-by":"crossref","unstructured":"Lavine SD et al. Gamma knife radiosurgery for metastatic melanoma: an analysis of survival, outcome, and complications. Neurosurgery, 1999. 44(1): 59\u201364; discussion 64\u20136.","DOI":"10.1097\/00006123-199901000-00031"},{"issue":"2","key":"2607_CR65","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jocn.2014.07.019","volume":"22","author":"J Sia","year":"2015","unstructured":"Sia J, et al. Stereotactic radiosurgery for 318 brain metastases in a single Australian centre: the impact of histology and other factors. J Clin Neurosci. 2015;22(2):303\u20137.","journal-title":"J Clin Neurosci."},{"issue":"3","key":"2607_CR66","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ijrobp.2012.05.047","volume":"85","author":"A Likhacheva","year":"2013","unstructured":"Likhacheva A, et al. Predictors of survival in contemporary practice after initial radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys. 2013;85(3):656\u201361.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"11","key":"2607_CR67","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","volume":"10","author":"EL Chang","year":"2009","unstructured":"Chang EL, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10(11):1037\u201344.","journal-title":"Lancet Oncol."}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-021-02607-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-021-02607-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-021-02607-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T06:06:15Z","timestamp":1675317975000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-021-02607-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,15]]},"references-count":67,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["2607"],"URL":"https:\/\/doi.org\/10.1007\/s12094-021-02607-8","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,15]]},"assertion":[{"value":"12 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The ethics approval from the german ethics committee is under the file reference 257\/16S dated 01.06.2016 for this project. All data have been collected retrospectively from anonymized data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}